Trial Profile
Open, Single-arm, Multicenter, Phase II Trial Investigating the Safety of Biweekly Cabazitaxel in Metastatic Castration Resistant Prostate Cancer Patients Previously Treated With a Docetaxel-containing Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Dec 2020
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms ProstyII
- 01 Dec 2020 Results published in the Anticancer Research.
- 07 Jun 2016 Status changed from recruiting to completed as results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 31 Mar 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-003156-39).